IV Medication for Agitation in Delirium in Older Patients
When IV medication is absolutely necessary for agitated delirium in older adults, parenteral antipsychotics (specifically haloperidol or ziprasidone) at the lowest effective dose should be used, while avoiding benzodiazepines—particularly midazolam—due to excessive adverse events and paradoxical worsening of agitation. 1
Critical First Principle: Minimize Parenteral Administration
The 2025 JAGS Geriatric Emergency Department Guidelines strongly emphasize that parenteral medications should be minimized and approached with extreme caution when treating older adults with agitated delirium 1. Oral medications should always be attempted first, as they are less coercive and safer. However, when IV administration becomes unavoidable due to severe agitation or inability to take oral medications, specific guidance exists.
Recommended IV Options
Parenteral Antipsychotics (Preferred)
Haloperidol remains the most commonly used IV antipsychotic for agitated delirium, though evidence for efficacy is limited 2. It can be administered as:
- Intermittent IV boluses at the lowest effective dose
- Continuous IV infusion for severe, refractory cases 3
Important caveat: Close monitoring for QTc prolongation and cardiac arrhythmias is mandatory with IV haloperidol 3.
Ziprasidone showed favorable safety in the 2025 JAGS review with zero adverse events (0/17 patients) and is available in parenteral formulation 1. However, the evidence base is limited with high risk of bias, preventing definitive recommendations.
What to Absolutely Avoid
Midazolam should NOT be used in older adults with agitated delirium 1. The 2025 JAGS guidelines found:
- Excessive adverse event risk
- Higher redosing rates (suggesting ineffectiveness)
- Potential for paradoxical worsening of agitation
- No additional benefits over other options
Do not co-administer antipsychotics with benzodiazepines in older adults—the data do not support this combination 1.
Dosing Strategy
Start with the lowest effective dose regardless of which agent you choose 1. The 2025 guidelines demonstrated clear dose-response relationships for adverse events, particularly:
- Respiratory complications with higher lorazepam doses
- Clinically relevant signals for droperidol and quetiapine dose-related toxicity
Older adults have altered pharmacokinetics and drug metabolism that increase susceptibility to adverse events 1.
Special Circumstances
Alcohol or Benzodiazepine Withdrawal
This represents the only scenario where benzodiazepines may be necessary in older adults with agitation 1. Even then, lorazepam is preferred over midazolam if a benzodiazepine must be used, though concerningly high adverse event frequencies occur with:
- Higher doses
- Parenteral administration 1
ICU Setting
Dexmedetomidine (an alpha-2 agonist) may be considered in the ICU for agitated delirium 4, 5. It showed:
- Potential reduction in delirium duration (moderate-quality evidence)
- Shorter mechanical ventilation duration
- Effective analgesia and anxiolysis without respiratory depression
However, it requires IV administration and close monitoring, limiting use outside intensive care settings 6, 4.
What Does NOT Work
The 2015 AGS guidelines explicitly state 7:
- Benzodiazepines should not be first-line treatment for agitation in delirium
- Cholinesterase inhibitors should not be newly prescribed for delirium treatment
- Antipsychotics and benzodiazepines should be avoided for hypoactive delirium
Monitoring Requirements
When using IV antipsychotics:
- Continuous cardiac monitoring for QTc prolongation
- Watch for extrapyramidal symptoms
- Monitor respiratory status
- Assess for paradoxical agitation
- Use the shortest possible duration 7
Evidence Quality Note
The 2025 JAGS guidelines represent the most current and highest-quality evidence available 1. However, they acknowledge that selecting a specific parenteral antipsychotic remains complicated because drug-to-drug comparisons showed no significant differences in most outcomes. The strongest evidence supports what NOT to do (avoid midazolam, avoid combination therapy) rather than identifying a single superior agent.